PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.

Hand-Foot Syndrome and Post-Progression Treatment Are the Good Predictors of Better Survival in Advanced Hepatocellular Carcinoma Treated with Sorafenib: A Multicenter Study.

Abstract To determine the relationship between treatment outcomes and hand-foot syndrome (HFS), and the relationship between survival rate and post-progression treatment after sorafenib therapy.
PMID
Related Publications

Clinical outcomes of patients with advanced hepatocellular carcinoma treated with sorafenib: a retrospective study of routine clinical practice in multi-institutions.

HATT: a phase IV, single-arm, open-label study of sorafenib in Taiwanese patients with advanced hepatocellular carcinoma.

Therapeutic decisions in the treatment of hepatocellular carcinoma and patterns of sorafenib use. Results of the international observational GIDEON trial in Spain.

Clinical parameters predictive of outcomes in sorafenib-treated patients with advanced hepatocellular carcinoma.

Indicators of sorafenib efficacy in patients with advanced hepatocellular carcinoma.

Authors

Mayor MeshTerms
Keywords

Hand-foot syndrome

Hepatocellular carcinoma

Sorafenib

Journal Title oncology
Publication Year Start


 


PMID- 29258090
OWN - NLM
STAT- MEDLINE
DCOM- 20171221
LR  - 20171221
IS  - 1423-0232 (Electronic)
IS  - 0030-2414 (Linking)
VI  - 93 Suppl 1
DP  - 2017
TI  - Hand-Foot Syndrome and Post-Progression Treatment Are the Good Predictors of
      Better Survival in Advanced Hepatocellular Carcinoma Treated with Sorafenib: A
      Multicenter Study.
PG  - 113-119
LID - 10.1159/000481241 [doi]
AB  - OBJECTIVE: To determine the relationship between treatment outcomes and hand-foot
      syndrome (HFS), and the relationship between survival rate and post-progression
      treatment after sorafenib therapy. METHODS: The study assessed 314 patients with 
      advanced hepatocellular carcinoma (HCC) treated with sorafenib at 5 general
      hospitals in Kagawa Prefecture, Japan. RESULTS: At the start of sorafenib
      therapy, 23.6% of the patients had HCC of a Child-Pugh class other than A. The
      initial sorafenib dose was 800 mg in 9.2% of the patients and 400 mg in 64.3%.
      Time to progression was 129 days (95% CI: 87.3-170.7) and the median overall
      survival (OS) was 392 days (95% CI: 316.0-468.0). The OS of the patients with
      Child-Pugh class A HCC was significantly better than that of the patients with
      Child-Pugh class B HCC (p < 0.0001). The survival curves for Child-Pugh class A-5
      points and class A-6 points were significantly different, with that for class A-5
      points being better (p < 0.0001). A significant difference was observed between
      the patients who exhibited HFS and those who did not, with the former exhibiting 
      a better survival rate (p < 0.001). In addition, the survival rate of the
      patients who received post-progression treatment after sorafenib therapy was
      significantly better than that of the patients who did not (p < 0.001).
      CONCLUSION: In sorafenib therapy, patients with HFS and those who received
      post-progression treatment exhibited good OS.
CI  - (c) 2017 S. Karger AG, Basel.
FAU - Ogawa, Chikara
AU  - Ogawa C
AD  - Department of Gastroenterology and Hepatology, Takamatsu Red Cross Hospital,
      Takamatsu, Japan.
FAU - Morita, Masahiro
AU  - Morita M
FAU - Omura, Akina
AU  - Omura A
FAU - Noda, Teruyo
AU  - Noda T
FAU - Kubo, Atsushi
AU  - Kubo A
FAU - Matsunaka, Toshihiro
AU  - Matsunaka T
FAU - Tamaki, Hiroyuki
AU  - Tamaki H
FAU - Shibatoge, Mitsushige
AU  - Shibatoge M
FAU - Tsutsui, Akemi
AU  - Tsutsui A
FAU - Senoh, Tomonori
AU  - Senoh T
FAU - Nagano, Takuya
AU  - Nagano T
FAU - Takaguchi, Kouichi
AU  - Takaguchi K
FAU - Tani, Joji
AU  - Tani J
FAU - Morishita, Asahiro
AU  - Morishita A
FAU - Yoneyama, Hirohito
AU  - Yoneyama H
FAU - Masaki, Tsutomu
AU  - Masaki T
FAU - Moriya, Akio
AU  - Moriya A
FAU - Ando, Masaharu
AU  - Ando M
FAU - Deguchi, Akihiro
AU  - Deguchi A
FAU - Kokudo, Yasutaka
AU  - Kokudo Y
FAU - Minami, Yasunori
AU  - Minami Y
FAU - Ueshima, Kazuomi
AU  - Ueshima K
FAU - Sakurai, Toshiharu
AU  - Sakurai T
FAU - Nishida, Naoshi
AU  - Nishida N
FAU - Kudo, Masatoshi
AU  - Kudo M
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
DEP - 20171220
PL  - Switzerland
TA  - Oncology
JT  - Oncology
JID - 0135054
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Phenylurea Compounds)
RN  - 0 (Protein Kinase Inhibitors)
RN  - 25X51I8RD4 (Niacinamide)
RN  - 9ZOQ3TZI87 (sorafenib)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Antineoplastic Agents/adverse effects/therapeutic use
MH  - Carcinoma, Hepatocellular/drug therapy
MH  - Female
MH  - Hand-Foot Syndrome/*etiology
MH  - Humans
MH  - Liver Neoplasms/drug therapy
MH  - Male
MH  - Middle Aged
MH  - Niacinamide/*analogs & derivatives/therapeutic use
MH  - Phenylurea Compounds/*therapeutic use
MH  - Prognosis
MH  - Protein Kinase Inhibitors/adverse effects/therapeutic use
MH  - Survival Rate
MH  - Treatment Outcome
OTO - NOTNLM
OT  - Hand-foot syndrome
OT  - Hepatocellular carcinoma
OT  - Sorafenib
EDAT- 2017/12/20 06:00
MHDA- 2017/12/22 06:00
CRDT- 2017/12/20 06:00
PHST- 2017/12/20 06:00 [entrez]
PHST- 2017/12/20 06:00 [pubmed]
PHST- 2017/12/22 06:00 [medline]
AID - 000481241 [pii]
AID - 10.1159/000481241 [doi]
PST - ppublish
SO  - Oncology. 2017;93 Suppl 1:113-119. doi: 10.1159/000481241. Epub 2017 Dec 20.